Navigation Links
Aethlon Medical Announces Launch of Exosome Sciences Subsidiary
Date:9/12/2013

SAN DIEGO, Sept. 12, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today announced the formal launch of Exosome Sciences, Inc. (ESI), a wholly-owned subsidiary previously established by Aethlon to pursue exosome-based strategies to diagnose and monitor the progression of cancer, infectious disease and other life-threatening conditions. Exosomes produced by diseased cells represent an optimal diagnostic target as they are shed into bodily fluids such as urine and blood where they can be easily accessed. Exosomes transport specific disease-origin markers that provide the basis for ESI to establish non-invasive liquid biopsies to diagnose and monitor a wide-range of disease conditions.

(Logo: http://photos.prnewswire.com/prnh/20130912/LA78266LOGO)

(Photo:  http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)

Aethlon Chairman and CEO, Jim Joyce stated, "As a therapeutic organization, our primary focus is the clinical advancement and future commercialization of the Aethlon Hemopurifer® in the United States and abroad.  With this mind, our objective with ESI is to transform a currently dormant and unvalued diagnostic asset into a stand-alone organization that contributes measurable asset value to Aethlon shareholders, yet does not dilute our team's focus away from advancing first-in-class therapeutic devices. It also became clear that the launch of ESI might allow us to leverage recent valuations that have been awarded to molecular diagnostic organizations with novel technology strategies." 

Aethlon disclosed that ESI's research facility is being established within a CLIA certified laboratory located in Langhorne, Pennsylvania.  The facility is adjacent to the Philadelphia/Ne
'/>"/>

SOURCE Aethlon Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Aethlon Medical to Present at Exosomes and Circulating Biomarkers 2013 Summit
2. Aethlon Medical Announces the Appointment of Chetan S. Shah, M.D. to its Board of Directors
3. Aethlon Medical Discloses Cancer and Infectious Disease Therapy Presentation at ISEV 2013
4. Aethlon Medical (AEMD) Note: New Government Contract, Resubmission of IDE to Treat Hepatitis C (HCV), Biothreat Legislation Signed into Law by President Obama
5. Aethlon Medical (AEMD) Note: Multiple Shots on Goal - A Therapeutic Strategy to Address Infectious Disease & Cancer
6. Aethlon Medical, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
7. Aethlon Medical (AEMD) Note: Since September 30th, 2011 / Thank You Shareholders
8. Aethlon Medical Discloses CEO Interview
9. Aethlon Medical (AEMD) Note: Extracorporeal Methods to Reduce Inflammation in Sepsis
10. Aethlon Medical To Present Today At The 15th International Conference On Dialysis
11. Aethlon Medical Announces the Appointment of Laszlo Radvanyi, Ph.D. to its Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014  A central New ... temporary Total Artificial Heart implant is home, ... with the Freedom® portable driver to wait for ... 64-year-old retiree from a Syracuse architectural hardware company, ... condition with medications, an implantable defibrillator and a ...
(Date:7/22/2014)... 2014 The Intellectual Property ... the world,s leading provider of intelligent information ... Cortellis Clinical Trials Intelligence , its global ... with the documentation of more than 180,000 ... greater and quicker access to critical data ...
(Date:7/22/2014)... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... company with operations in China and ... it will release financial results for the second quarter of ... August 13, 2014 (which will be Thursday morning, August 14, ... the investor relations section of the Company,s website at ...
Breaking Medicine Technology:'I'm a Heartless SOB' Jokes Patient Discharged from Strong Memorial Hospital without a Human Heart 2'I'm a Heartless SOB' Jokes Patient Discharged from Strong Memorial Hospital without a Human Heart 3Thomson Reuters Cortellis Clinical Trials Intelligence Reaches Industry Milestone with 180,000 Clinical Trials 2Thomson Reuters Cortellis Clinical Trials Intelligence Reaches Industry Milestone with 180,000 Clinical Trials 3WuXi PharmaTech Schedules Second-Quarter 2014 Earnings Release 2
... Phase 1 Clinical Trial Results Disclosed, ... Inc., a,biopharmaceutical company developing "Best-in-Class" drugs for ... that the results,of multiple studies on its ... will be presented in eighteen presentations at ...
... CeNeRx BioPharma,Inc., a clinical stage company developing and ... system, today announced that,it has initiated a Phase ... for the treatment of major depressive disorder (MDD). ... novel class of drugs known as RIMAs,or reversible ...
Cached Medicine Technology:Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA 2Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA 3CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM) 2CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM) 3
(Date:7/22/2014)... 22, 2014 CyraCom has been ranked ... in the translation and interpreting industry. Released June 2014 ... report titled "The Language Services Market: 2014," also ranked ... world, moving up two spots from 2013. , In ... LSPs that provide interpretation services – a subset of ...
(Date:7/22/2014)... The Muscular Dystrophy Association (MDA) and Jiffy Lube today ... campaign that will raise funds to help save and ... muscle disease. , As part of the campaign, ... centers through Sept. 1, 2014 to make a donation to ... the fight for muscle health. Since 2012, Jiffy Lube has ...
(Date:7/22/2014)... Paul, Minn. (PRWEB) July 22, 2014 ... dental comfort technology, the Restful Jaw ®. The ... the patient’s jaw while minimizing jaw pain, fatigue and ... can experience shorter treatment times when patients do not ... pain. , The Restful Jaw is a vital ...
(Date:7/22/2014)... HealthDay Reporter MONDAY, July 21, 2014 (HealthDay ... asthma appears to offer relief to people with chronic hives ... The prescription drug -- omalizumab (Xolair) -- is already ... approval earlier this year for that use. The current ... dose for a six-month period it seems to be both ...
(Date:7/22/2014)... at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute ... one of the most complex and difficult-to-treat forms ... , Locally advanced pancreatic cancer has the lowest ... cumulative five-year survival rate of only 4 percent ... an option for patients because tumors often involve ...
Breaking Medicine News(10 mins):Health News:CyraCom Ranked Among the World’s Largest Language Service Providers 2Health News:Jiffy Lube® Supports Fight Against Muscle Disease with Third Annual MUSCLE UP® Campaign 2Health News:Jiffy Lube® Supports Fight Against Muscle Disease with Third Annual MUSCLE UP® Campaign 3Health News:Introducing the Restful Jaw – The Only Device Designed to Protect the Patient’s Jaw 2Health News:Introducing the Restful Jaw – The Only Device Designed to Protect the Patient’s Jaw 3Health News:Asthma Drug May Help Those With Chronic Hives 2Health News:Asthma Drug May Help Those With Chronic Hives 3Health News:Unique study focuses on combined treatment approach for locally advanced pancreatic cancer 2Health News:Unique study focuses on combined treatment approach for locally advanced pancreatic cancer 3
... Health Plans Offer Broader ChoiceEAGAN, Minn., April 13 ... today announced the largest array of individual health plan ... buy health insurance on their own. The new plans ... series of "design your own health plan" sessions, in ...
... 13 The American Heart Association, with support from ... three research centers to study the development and mechanisms ... next four year, the centers will be conducting studies ... help improve outcomes for heart attack and heart failure ...
... 5,000 years ago , , MONDAY, April 13 (HealthDay News) -- ... stomach,s sake," may have been heeded more than 5,000 years ... residues found in wine jars left in the tomb of ... had been steeped in herbs including balm, coriander, mint and ...
... Jean Nordin Evans, DDS, FIND and Dr. Robert Evans, DMD, FIND, FAGD ... new medical center located at Mill Run Plaza. , ... Groton, MA ... visionary, announced today that Groton Wellness Medical Center has opened its doors ...
... beyond mere placebo effect , , MONDAY, April 13 (HealthDay ... a 25 percent less nausea during radiation treatments, a new ... Journal of Pain and Symptom Management , also discounted ... as a placebo than an actual pain reliever. , ...
... 13 The Advertising Council, in partnership,with Autism Speaks, ... public,service advertisements (PSAs) featuring professional golfer Ernie Els, and ... about autism and to urge,parents to learn the early ... in every 150 children. , , ...
Cached Medicine News:Health News:Blue Cross Launches Largest Selection of Individual Plans Available in Minnesota 2Health News:Blue Cross Launches Largest Selection of Individual Plans Available in Minnesota 3Health News:Three Medical Centers Awarded Funds to Study Generation of Cardiac Muscle Cells 2Health News:Pharoah's Wine Jar Yields Medicinal Secrets 2Health News:Pharoah's Wine Jar Yields Medicinal Secrets 3Health News:Top Medical and Dental Team Opens Groton Wellness Medical Center in Groton, MA 2Health News:Top Medical and Dental Team Opens Groton Wellness Medical Center in Groton, MA 3Health News:Top Medical and Dental Team Opens Groton Wellness Medical Center in Groton, MA 4Health News:Wristbands May Lessen Nausea After Radiation 2Health News:Video: The Advertising Council and Autism Speaks Launch New PSAs to Raise Awareness of Autism 2Health News:Video: The Advertising Council and Autism Speaks Launch New PSAs to Raise Awareness of Autism 3Health News:Video: The Advertising Council and Autism Speaks Launch New PSAs to Raise Awareness of Autism 4
Tennant angled tying forceps with extra delicate smooth jaws, 6 mm tying platform, For 9-0 to 11-0 sutures. Overall length 108 mm....
Catalano angled tying forcep has 6 mm V-grove tying platform. Overall length 100 mm....
Catalano straight tying forcep has 6 mm V-grove tying platform. Overall length 100 mm....
Kelman - McPherson angled tying forceps is long with tying platform 10 mm, serrated handle and polished finish....
Medicine Products: